FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

FDA lift clinical hold on Adolors Entereg (alvimopan) program for chronic opioid bowel dysfunction (OBD).

Merck publish series of Quinazolinone Histamine H3 Receptor Inverse Agonists

Merck have published a new series of quinazolinone Histamine H3 Receptor Inverse Agonists

SkyePharmas Third Flutiform Phase III Study meets endpoints

SkyePharma have announced that its third Phase III trial of Flutiform in asthma patients has met its primary endpoints.

Shire to acquire Jerini adding Bradykinin antagonist Icatibant to portfolio

Shire has proposed the acquisition of biotechnology company Jerini AG with which it will acquire hereditary angioedema product, Icatibant (Firazyr). Icatibant is a peptide Bradykinin B2 receptor antagonist

Senetek terminate license agreement with Ardana for Invicorp

Senetek have terminated a license agreement with Ardana for Invicorp due to Ardana’s entry into voluntary administration on June 27, 2008.

Movetis Vasopressin 2 antagonist M0002 enters Phase IIb trials for cirrhotic ascites

Movetis have announced that its vasopressin receptor 2 antagonist M0002 will move in to Phase IIb trials for cirrhotic ascites

Almirall and Forest complete Phase III trials of Aclidinium in COPD

Almirall and Forest have announced that Phase III trials of Aclidinium in COPD are now complete

EU approves Relistor for Opioid-Induced Constipation In Advanced Illness Patients

Wyeth and Progenics have received marketing approval for Relistor (methylnaltrexone bromide) subcutaneous injection in the EU for the treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.